Adverse drug reactions (ADRs) induced from high-order drug-drug interactions (DDIs) due to polypharmacy represent a significant public health problem. In this paper, we formally formulate the to-avoid and safe (with respect to ADRs) drug recommendation problems when multiple drugs have been taken simultaneously. We develop a joint model with a recommendation component and an ADR label prediction component to recommend for a prescription a set of to-avoid drugs that will induce ADRs if taken together with the prescription. We also develop real drug-drug interaction datasets and corresponding evaluation protocols. Our experimental results on real datasets demonstrate the strong performance of the joint model compared to other baseline methods.
of another drug, leading to unpredictable clinical consequences. DDIs were responsible for approximately 26% of the ADRs, affected 50% of inpatients [14] , and caused nearly 74,000 emergency room visits and 195,000 hospitalizations annually in the US [13] . The increasing popularity of polypharmacy continues to expose a significant and growing portion of the population to unknown or poorly understood DDIs and associated ADRs. The National Health and Nutrition Examination Survey [5] reports that more than 76% of the elderly Americans take two or more drugs every day. Another study [8] estimates that about 29.4% of elderly American patients take six or more drugs every day. This has made understanding high-order DDIs and their associated ADRs urgent and important.
Current research on DDIs and their associated ADRs is primarily focused on mining and detecting DDIs for knowledge discovery (literature review in Section 2.1). In applying the knowledge in practice for preventive, proactive and person-centered healthcare, it also requires predictive power to deal with unknowns and uncertainties, and to provide evidence-based suggestions to facilitate future drug use. As wet-lab based experimental validation scheme for DDI study still falls behind due to its low throughput and lack of scalability, but meanwhile huge amounts of electronic medical record data become increasingly available, data-driven computational methodologies appear more appealing to tackle DDI and ADR problems. Unfortunately, computational effects to facilitate future polypharmacy, particularly to assist safe multi-drug prescription, are still in their infancy.
In this paper, we present a computational method toward the goal of assisting future safe multi-drug prescriptions. Here we use the term "prescription" to represent a set of drugs that have been taken together, even though there could be non-prescription drugs. Thus, we tackle the following to-avoid drug recommendation problem and safe drug recommendation problem. Definition 1. To-avoid Drug Recommendation: given the multiple drugs in a prescription that have been taken simultaneously, recommend a short ranked list of drugs that should be avoided taking together with the prescription in order to avoid a particular ADR.
Definition 2. Safe Drug Recommendation: given the multiple drugs in a prescription that have been taken simultaneously, recommend a short ranked list of safe drugs that, if taken together with the prescription, are not likely to induce a particular ADR.
Please note that in this study we only consider one ADR and thus drug safety is only considered with respect to that ADR. To the best of our knowledge, this is the first work to formally formulate the above problems and provide a computational solution framework.
The above two recommendation problems are significant particularly for healthcare practice. They can enable evidence-based suggestions to help polypharmacy decision making, and induce novel hypotheses on new high-order DDIs and associated ADRs. These problems are different from traditional product recommendation problems in e-commerce, in which no label information is involved on a set of user's previous purchased products as a whole (each product is analogous to a drug; a set of previous purchased products is analogous to a prescription). In addition, ADRs induced from a set of drugs could be due to pharmaceutical, pharmacokinetic or pharmacodynamic interactions among only a (unknown) subset of the drugs. In e-commerce recommendation problems, the notion of subset synergy and interactions is very weak. Due to the above reasons, the to-avoid drug recommendation and safe drug recommendation problems are inherently very non-trivial.
Our contributions to solving the two new drug recommendation problems are summarized as follows:
• We developed a joint sparse linear recommendation and logistic regression model (SlimLogR), with a drug recommendation component and an ADR label prediction component (Section 5).
The recommendation component captures drug co-prescription patterns among ADR and non-ADR inducing prescriptions, respectively, and uses such patterns to recommend drugs. The ADR label prediction component re-ranks all the recommended drugs based on their ADR probabilities to produce final recommendations. These two components are learned concurrently in SlimLogR so that the recommended drugs are more likely to introduce expected ADR labels.
• We developed a protocol to mine high-order DDIs and their associated ADRs, and provided a DDI dataset to the public 1 (Section 7).
• We developed new evaluation protocols and evaluation metrics to evaluate the performance of drug recommendation (Section 8).
• We conducted comprehensive experiments to evaluate SlimLogR, and provided case study on recommended drugs (Section 9). Our experiments demonstrate strong performance of SlimLogR compared to other methods.
RELATED WORK 2.1 DDI and ADR Study
Significant research efforts have focused on detecting DDIs. These efforts can be broadly classified into four categories [17] .
Methods of the first category analyze medical literature and/or electronic medical records, and extract mentioned drug pairs [8] . Methods in the second category integrate various biochemical and molecular drug/target data to measure drug-drug similarities and score/predict pairwise DDIs. These data include target information [17] , phenotypic and genomic information [2] , and drug side effects [16] , etc. Methods of the third category leverage healthcare information on social media and online communities to detect DDIs [19] . The 1 The dataset will be publicly available upon the acceptance of this paper fourth category focuses on using numerical models to predict the dose responses to multiple drugs [3] . A recent thread is dedicated to understanding the interaction patterns among high-order DDIs, and how such patterns can relate to induced ADRs [12] .
Recommender Systems
Top-N recommender systems, which recommend the top-N items that are most likely to be preferred by users, have been used in a variety of applications in e-commerce, social networking and healthcare, etc. The methods can be broadly classified in two categories. The first category is the neighborhood-based collaborative filtering methods [11] , which produce recommendations based on similar users or similar items. The second category is model-based methods, particularly latent factor models [15] that factorize the user-item matrix into (low-rank) user factors and item factors, and predict user preference over items using the latent factors. Recent recommender systems have also been advanced by the significant contribution from deep learning [21] , where user preferences and item characteristics can be learned in deep architectures. On the other hand, recommender systems methods have also been integrated with regression methods to tackle joint problems of missing value recovery and prediction [9] . Recommender systems have been recently applied to prioritizing healthcare information, due to a tremendous need for personalized healthcare [18] . Current applications along this line include recommending physicians to patients on specific diseases [7] , recommending drugs for patient symptoms [20] , recommending nursing care plans [4] , and therapy decision recommendation [6] . However, to the best of our knowledge, very little research has been done on new prescription recommendation particularly with ADR concerns.
DEFINITIONS AND NOTATIONS
In this paper, we use d to represent a drug, and a binary matrix A ∈ R m×n to represent prescription data. Each row of A represents a prescription, denoted as a i (i = 1, · · · , m), and each column of A corresponds to a drug. Thus, there are m prescriptions and n drugs in total represented by A. If a prescription a i contains a drug d j , the j-th entry in a i (i.e., a i, j ) will be 1, otherwise 0. Thus, a i is a binary row vector representing the existence of drugs in the i-th prescription. Note that all the prescriptions are unique in A. Drug dosage in prescriptions is not considered in this study. When no ambiguity arises, the terms "a prescription" and "a binary vector a" are used exchangeably, and "a set of prescriptions" and "a matrix A" are also used exchangeably. In addition, a label y i is assigned to a i to indicate whether a i induces a certain ADR (denoted as y i = 1 or y + i ) or not (denoted as y i = −1 or y − i ). In this paper, we only consider one ADR and thus the labels are binary. In addition, superscript + indicates information/data related to ADR induction (i.e., positive information), superscript − indicates information/data related to no ADR induction (i.e., negative information) and accent A indicates estimated A.
BACKGROUND 4.1 SLIM for top-N Recommendation
Sparse Linear Method (SLIM) [10] is an efficient and state-of-the-art algorithm for top-N recommendation that was initially designed for e-commerce applications. In the drug recommendation problem, given a drug prescription a i , SLIM models the score of how likely an additional drug d j should be co-prescribed with a i as a sparse linear aggregation of the drugs in a i , that is,
whereã i j is the estimated score of d j in a i (can have values rather than 0 and 1), and w ⊺ j is a sparse column vector of aggregation coefficients. Note that a i j = 0, that is, d j is not included a i originally. Drugs with high scores calculated as above will be recommended to the prescription. Thus, the scores are referred to as recommendation scores, and a prescription composed of a i and a recommended drug d j is referred to as a new prescription with respect to a i , denoted as a i ∪ {d j }. The intuition of using SLIM for to-avoid drug recommendation will be discussed later in Section 5.1.1.
To
where
|w i j | is the entry-wise ℓ 1 -norm of W , and ∥·∥ F is the matrix Frobenius norm. The SLIM formulation can also be considered as a way to reconstruct A by itself through learning the patterns (i.e., W ) in A. Therefore, W converts a binary A into its estimationÃ of floating values, which cover recover unseen non-zero entries in A.
Logistic Regression for Label Prediction
We can formulate the problem of predicting whether a prescription of multiple drugs induces a particular ADR as a binary classification problem, and solve the problem using logistic regression (LogR). In LogR, the probability of a prescription a i inducing the ADR is modeled as follows,
where x ⊺ and c are the parameters. To learn the parameters, LogR solves the following optimization problem, min
LogR(y|A; x, c, β, γ )
DRUG RECOMMENDATION 5.1 Joint Sparse Linear Recommendation and Logistic Regression Model
We propose a novel model to conduct the task of to-avoid and safe drug recommendation to existing prescriptions. The model recommends a set of additional to-avoid drugs to an existing prescription such that each of the recommended drugs should not be taken together with the prescription in order to avoid ADRs. The model also recommends safe drugs that can be taken together with the prescription. This novel model consists of a drug recommendation component and an ADR prediction component. The recommendation component is instantiated from SLIM (Section 4.1), and the ADR prediction component uses logistic regression LogR (Section 4.2).
This model is referred to as joint sparse linear recommendation and logistic regression model and denoted as SlimLogR. SlimLogR learns the SLIM and LogR components jointly through solving the following optimization problem.
In SlimLogR, A + /A − is a set of training prescriptions known to induce ADRs/not to induce ADRs, respectively, andÃ + /Ã − is the respective estimation from a SLIM model (Equation 1) , that is,
where W + and W − are the SLIM model parameters. In addition, M is a mask matrix that selects values inÃ in predicting y (i.e., the ADR labels on A prescriptions) in the LogR component, and • is the entry-wise Hadamard product.
Learning Co-Prescription Patterns via SLIM. SlimLogR learns drug co-prescription patterns using
, that is, whether a drug should be included in a prescription is modeled as a linear function of other drugs that are included in the prescription. This modeling scheme is motivated by the existence of strong co-prescription drug pairs as we observe from real data (Section 9.4). Meanwhile, linearality is a simplistic relation to model the co-prescription patterns, in which larger coefficients represent stronger co-prescription relation. Note that the zero-diagonal constraint on the coefficient matrix W in SLIM (i.e., diag(W + ) = 0, diag(W − ) = 0 in Equation 5) excludes the possibility that a drug is co-prescribed with itself. In addition, the non-negativity constraint on W (i.e., W + ≥ 0, W − ≥ 0 in Equation 5) ensures that the learned relation is on drug co-appearance. The regularization term ∥W ∥ ℓ 1 induces sparsity in W because not all the drugs tend to be co-prescribed.
In SlimLogR, the patterns in ADR inducing and non-ADR inducing prescriptions are modeled using two SLIM models (i.e., A + = A + W + andÃ − = A − W − ) because it is expected these two patterns are different, and thus the prospectively learned W + and W − will present different patterns. The pattern difference is indicated during the data pre-processing (Section 7.1 and 7.2, Table 2 ). The W coefficients in the SLIM component are learned by minimizing the difference between A andÃ estimated from SLIM. Note that A is a binary matrix butÃ can have floating values rather than 0 and 1. Once the linear aggregation parameter W is learned, it can be used to recommend additional drugs that are likely to be co-prescribed with an existing prescription.
Predicting ADR via
LogR. SlimLogR uses LogR to predict whether a prescription will induce ADRs or not (i.e.,
LogR produces a probability of ADR induction from a linear combination of drugs in a prescription (Equation 3), and these probabilities can be further used to rank such prescriptions. Note that the estimated prescriptionsÃ from SLIM rather than A is used to train LogR. This connects SLIM and LogR to further enforce that the SLIM component learns co-prescription patterns that better correlate with their ADR induction labels (i.e., y in Equation 5). Meanwhile, the use ofÃ also generalizes the ability of LogR to predict for new prescriptions, asÃ will have new drugs compared to A (as discussed in Section 4.1).
In LogR, M selects values inÃ in predicting y. We have the following two approaches to selecting M + and M − .
Inclusive SlimLogR (SlimLogR in ): In this approach, M = 1 (i.e., a matrix of all 1's), and therefore, all the drugs inÃ and their values will be used in the LogR component. The use of all these drugs plays the role to enforce that the SLIM component produces large recommendation scores on prescribed drugs in A and small scores on un-prescribed drugs. In this way, the prescribed drugs will dominate the label prediction in the LogR component in order to produce accurate label prediction. This approach is referred to as inclusive SlimLogR and denoted as SlimLogR in .
Exclusive SlimLogR (SlimLogR ex ): In this approach, M = I(A) where I is an indicator function ((I )(x) = 0 if x = 0, 1 otherwise), that is, only the prescribed drugs in A and their values are used to ensure that LogR is able to make accurate prediction. This approach is referred to as exclusive SlimLogR and denoted as SlimLogR ex .
Training SlimLogR
The optimization problem 5 can be solved through the alternating direction method of multipliers (ADMM) [1] . We introduce a new variable Z and thus the following augmented Lagrangian as the new objective to optimize:
where u + and u − are the Lagrange multipliers; ρ + , ρ − > 0 are the penalty parameters, and vec(·) is the vectorization of a matrix. The algorithm to solve the problem is presented in Algorithm 1. In Algorithm 1, to solve for W , the problem boils down to a regularized least squares problem and can be solved by gradient descent method. To solve for Z , the problem boils down to a combination of a regularized logistic regression problem and a least squares problem and can be solved by gradient descent method. To solve for x and c, the problem boils down to a regularized logistic regression problem and can be solved by gradient descent method. The algorithm empirically converges.
Applying SlimLogR
SlimLogR recommends drugs for each existing prescription a following a two-step procedure:
• Step 1: use the learned SLIM component to recommend a list of potential to-avoid/safe drug candidates {d r j };
and W −
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Step 2: for each recommended candidate dr j , combine it with a (i.e., a ∪ {d r j }) and use the learned LogR component to predict the ADR probability of the new prescription. Note that in LogR prediction, each recommended drug from SLIM is considered individually together with the prescription. It is also possible in real practice that multiple drugs all together should be avoided as they, together with the prescription, may induce ADRs. However, this problem is significantly more difficult as the synergy of high-order drug combinations is highly non-trivial to estimate. This problem will be tackled in our future research.
Recommendation from SLIM.
Given a prescription a, the recommendation scores of all drugs with respect to a are calculated asã + = aW + andã − = aW − , that is,ã + , the scores of being potential to-avoid drugs, are calculated from W + , andã − , the scores of being potential safe drugs, are calculated from W − . Based onã + andã − , the top-M scored drugs that are not in prescription a will be selected as to-avoid and safe drug candidates for a, respectively.
ADR Prediction and re-Ordering from
LogR. The to-avoid and safe drug candidates from SLIM are further predicted using LogR. For a prescription a i , each of its candidates will be combined with a i to form a new candidate to-avoid or safe prescription, denoted as r i (j) + (i.e., r i (j) + = a + i ∪ {d + r j }) and r i (j) − (i.e., That is, the to-avoid/safe drug candidates are only predicted for their labels as being true to-avoid/safe drugs. The drug candidates are then sorted based on their LogR prediction scores, respectively, and the top-N ranked drugs will be recommended. Thus, the SLIM step can be considered as an initial top-M recommendation and the LogR step can be considered as a secondary re-ordering of initial candidates for final recommendations. If f i (j) = r i (j), the prediction method is referred to as content-based prediction and denoted as LogR b . If f i (j) = s i (j), the prediction method is referred to as score-based prediction and denoted as LogR s .
6 COMPARISON METHODS 6.1 Random Method (Rand)
In the first comparison method, we fully randomly recommend drugs for each prescription as to-avoid drugs and safe drugs, respectively. This method is referred to as random method and denoted as Rand. Rand serves as a baseline in which no learning is involved.
Logistic Regression Only (LogR)
In this comparison method, only a LogR model is learned to predict ADR labels. Prescriptions that induce ADRs are used as positive training data, and prescriptions that do not induce ADRs are used as negative training data. No SLIM models are learned in this method. For a prescription a, each of all possible drugs that are not in a is first combined with a to form a new prescription. Then LogR is applied on the new prescription and produces a score of inducing ADRs. The drugs that lead to the highest/lowest prediction scores are recommended as the to-avoid/safe drugs. This method is referred to as logistic regression only and denoted as LogR.
Sparse Linear Method Only (SLIM)
In this method, a SLIM + model is learned on ADR inducing prescriptions, and a SLIM − model is learned on non-ADR inducing prescriptions. For a prescription, the top drugs recommended from SLIM + are considered as to-avoid drugs, and the top drugs recommended from SLIM − are considered as safe drugs. This method is referred to as SLIM only and denoted as SLIM.
Separate Models (SLIM+LogR)
In this method, a SLIM and a LogR model are built separately, and used together for recommendation. Specifically, a SLIM + and a SLIM − as in SLIM only are learned first. Meanwhile, a LogR model is also learned independently. The top recommendations from SLIM + /SLIM − are then predicted using the LogR model, and the top-scored drugs are recommended as to-avoid/safe drugs. That is, the recommendation process of this method is identical to that of SlimLogR. The difference is that SLIM and LogR are learned independently, not jointly as in SlimLogR. This method is referred to as separate SLIM-LogR model and denoted as SLIM+LogR.
MATERIALS 7.1 Mining Prescriptions
We first extracted high-order drug combinations from FDA Adverse Event Reporting System (FAERS) 2 . We use myopathy as the ADR of particular interest, and extract 64,892 case (myopathy) events, in which patients report myopathy after taking multiple drugs, and 1,475,840 control (non-myopathy) events, in which patients do not report myopathy after taking drugs. Each of these events involves a combination of more than one drug. Each drug combination is considered as a prescription. Among all the involved prescriptions, 10,250 unique prescriptions appear in both case and control events. For those 10,250 prescriptions, we use Odds Ratio (OR) to quantify their ADR risks. The OR for a prescription a is defined based on the contingency table 1, and is the ratio of the following two values: 1). the odds that the ADR occurs when a is taken (i.e., Table 1 ); and 2). the odds that the ADR occurs when a is not taken (i.e., Table 1 ). OR < 1 indicates the decreased risk of ADR after a patient takes the prescription, OR = 1 indicates no risk change, and OR > 1 indicates the increased risk. In the 10,250 prescriptions, 8,986 prescriptions have OR > 1 and 1,264 prescriptions have OR < 1. These two sets of prescriptions are denoted as A + 0 and A − 0 , respectively. In addition to these prescriptions, there are 27,387 unique prescriptions that only appear in case events and 621,449 unique prescriptions that only appear in control events. These two sets are denoted as A + + and A − − , respectively. The set of prescriptions in case events is denoted as A + (i.e., A + = A + + ∪ A + 0 ) and is used as the positive set. The set of prescriptions in control events is denoted as A − (i.e., A − = A − − ∪A − 0 ) and is used as the negative set. All these four sets together define a prescription dataset from FAERS, denoted as A FAERS . Table 2 presents the statistics of A FAERS . Here, "#{a }" and "#{d }" represent the number of prescriptions and the number of involved drugs, respectively. In each set of prescriptions, "avgOrd"/"avgFrq"/"avgOR" is the average number of drugs/average frequency/average OR of all prescriptions.
Note that the reason for myopathy as the only ADR is that myopathy has been well studied and well understood compared to other ADRs in terms of the drugs and drug mechanisms that induce myopathy. Such knowledge will well support retrospective evaluation and validation on drug recommendation with respect to myopathy. On the other hand, multiple ADRs will introduce substantial difficulty to the recommendation problem, and thus will be tackled in future research.
Training Data Generation
As shown in Table 2 Table 2 presents the description of A * . Note that A * is the set of labeled prescriptions that are used for model training.
Note that the prescriptions in A − do not induce myopathy, but they may induce other ADRs because all prescriptions in FEARS are reported as inducing ADRs. Therefore, A − is not truly negative (i.e., free of ADRs) and only negative with respective to myopathy. Similarly, when safe drugs are referred to, they represent safety in terms of myopathy, but not necessarily free of any ADRs.
EVALUATION PROTOCOLS AND METRICS 8.1 Five-Fold Cross Validation
The performance of different methods is evaluated through five-fold cross validation. The dataset A * is randomly split into five folds of equal size (i.e., same number of prescriptions). Four folds are used for model training and the rest fold is used for testing. In the fold for testing, one drug is randomly selected and removed from each prescription. If the prescription after drug removal actually induces ADRs, it is removed from the testing set. Then the to-avoid/safety drugs will be recommended for the rest of the prescription. This is to make sure that it is the recommended to-avoid drugs that introduce DDIs and thus ADRs. This process is performed five times, with one fold for testing each time. The final result is the average out of the five experiments. In each split, the corresponding training set is denoted as A * t r n , and the testing set is denoted as A * t st .
Knowledge Pool Generation
To evaluate the performance of various methods, we first define a knowledge pool of labeled prescriptions, denoted as A pool , which the recommended new prescriptions can be searched from and evaluated against. This knowledge pool serves as the entire knowledge space which is unknown during training. For a particular training set A * t r n , A pool can be either A * \ A * t r n (i.e., A pool is actually A * t st in this case) or A FAERS \ A * t r n (i.e., A pool is much larger than A * t st ). Note that A * t r n is excluded from A pool because we can always search testing prescriptions in A * t r n (i.e., known labeled prescriptions) in order to identify corresponding to-avoid prescriptions in A * t r n , and therefore no recommendations will be needed. By excluding A * t r n from A pool , we care about recommending particularly to-avoid/safe drugs to prescriptions such the new prescriptions have not been observed before. We believe this application is of more interest and significance in real practice.
Evaluation Metrics
Each of the methods will generate N recommended to-avoid/safe drugs for each testing prescription. Given A pool , the performance of these methods is evaluated using the following three metrics.
Normalized Truncated Recall (rec t ) is denoted as rec t and defined as follows,
where #TP is the number of recommended to-avoid prescriptions for testing prescriptions that appear in A pool + , and #P is the number of all to-avoid prescriptions for testing prescriptions in A pool + .
Note that the maximum possible value of rec t (max(rec t )) can be smaller than 1. This is because for each testing prescription, the number of its true to-avoid prescriptions existing in A pool + (i.e., #P)
can be more than the number of recommended prescriptions (i.e., N ) that is allowed and therefore more than #TP. Note that for each testing prescription, only top-N to-avoid drugs are recommended, where N is a small number. Normalized Truncated Precision (prec t ) is denoted as prec t and defined as follows
where #FP is the number of recommended to-avoid prescriptions for testing prescriptions that are not in A pool + , and thus #TP + #FP is the number of total recommended to-avoid prescriptions. Note that the maximum possible value of prec t can be smaller than 1. This is because for each testing prescription, the number of its true to-avoid prescriptions existing in A pool + (i.e., #P) can be smaller than the number of recommended prescriptions (i.e., N ) that is allowed, and therefore #TP is smaller than #TP + #FP. Normalized Truncated Accuracy (acc t ) is denoted as acc t and calculated as follows,
where #TN/#FN is the number of recommended safe prescriptions that do exist/do not exist in A pool − . Note that the maximum possible value of acc t can be smaller than 1. This is due to a similar reason as for prec t < 1, that is #TP can be smaller than #TP + #FP, and #TN can be smaller than #TN + #FN. Note that we did not use conventional ranking-based metrics such as average precision at k because we believe in clinical practice of multi-drug prescription, people care whether all the to-avoid drugs can be correctly recommended (i.e., a notion of recall) much more than how the to-avoid drugs are ranked.
EXPERIMENTAL RESULTS
The presented experimental results in this section are more focused on to-avoid drug recommendation due to space limit. In addition, to-avoid drug recommendation is of more clinical significance compared to safe drug recommendation. The column "mdl" corresponds to models. The column "prd" corresponds to prediction methods. The best rec t is underlined. The best overall performance is bold. The column "mdl" corresponds to models. The column "prd" corresponds to prediction methods. The best prec t is underlined. The best overall performance is bold. Table 3 , 4 and 5 present the performance of different methods in terms of their best rec t , best prec t and best acc t , respectively, and the values on the other two evaluation metrics when each respective best performance is achieved. Optimal parameters are not presented in the tables due to space limit. In these tables, SlimLogR first recommends 20 drugs from its SLIM component, and then its LogR component produces top-5 (i.e., N = 5) scored drugs as to-avoid drug recommendations. In terms of best rec t as in Table 3 , when A FAERS is used as A pool , SlimLogR in achieves the best performance (rec t = 0.2361), which is 11.0% better than the second best method SLIM and SLIM+LogR. When A * is used as A pool , SlimLogR in also achieves the best performance (rec t = 0.2618), which is 5.6% better than the second best method SlimLogR ex , and 6.0% better than The column "mdl" corresponds to models. The column "prd" corresponds to prediction methods. The best acc t is underlined. The best overall performance is bold.
Method Comparison
SLIM and SLIM+LogR. This indicates the power of joint learning of SLIM recommendation component and LogR prediction component in SlimLogR. Meanwhile, SlimLogR performs at least 39-fold better than Rand on A FAERS as A pool , and at least 90-fold better on A * as A pool . This indicates the strong ability of SlimLogR in discovering true to-avoid drugs. On the other hand, LogR is a strong baseline because it is at least 34-fold better and 61-fold better than Rand in the two A pool cases. SLIM is even stronger than LogR in discovering true to-avoid drugs, as it is 2.2% and 38.7% better than Rand in the two A pool cases. However, when LogR or SLIM is used alone, they are not any better than being used together in SLIM+LogR, whereas the latter is still behind SlimLogR. Very similar trends exist in Table 4 and 5. In terms of best prec t as in Table 4 , SlimLogR outperforms the second best methods SLIM and SLIM+LogR at 10.9% and 6.0% in the two A pool cases, respectively. In terms of best acc t as in Table 5 , SlimLogR outperforms the second best methods SLIM and SLIM+LogR at 4.9% and 2.0% in the two A pool cases, respectively. More importantly, SlimLogR achieves the overall best rec t , best prec t and best acc t almost at the same time. For example, when SlimLogR in achieves best rec t 0.2361 as in Table 3 , its corresponding prec t 0.2361 is its best prec t as in Table 4 , and its corresponding acc t 0.2958 is same as its best acc t 0.2958 in Table 5 . This indicates the strong capability of SlimLogR in accurately recovering true in-avoid drugs and also true safe drugs.
It is notable in Table 3 , 4 and 5 that SlimLogR in consistently outperforms SlimLogR ex in rec t , prec t and acc t . SlimLogR in uses all the drugs and their scores recommended by its SLIM component in its LogR component, whereas SlimLogR ex only uses the drugs that are already in corresponding prescriptions and their scores by SLIM in LogR. The use of all drugs from SLIM in LogR may enable SlimLogR to better learn its SLIM component and better capture the co-prescription relations among drugs that further lead to their ADR labels. Meanwhile, it may generalize the capability of its LogR component to better predict new prescriptions, not to overfit on known prescriptions.
It is also notable that the recommendation method LogR b and LogR s (Section 5.3.2) do not make a significant difference. They almost achieve identical performance given a certain SlimLogR method as in Table 3 , 4 and 5. This may be due to the fact that the SLIM and LogR components together in SlimLogR are able to recover strong co-prescription patterns that closely correlate to prescription ADR labels, and thus the patterns have their recommendation scores close to binary. Table 6 , 7 and 8 present the parameter study on ω and α as in Equation 5 on SlimLogR in with LogR s for top-5 (i.e., N = 5) toavoid drug recommendations. The pool A pool is set to A FAERS . In SlimLogR, ω controls the weight of LogR component and α controls the Frobenius-norm regularizations in SLIM component. We don't present the parameter study over other parameters here. This is because in our study, it is observed that SlimLogR requires a very small λ (i.e., the parameter for the ℓ 1 -norm regularizations in SLIM component), for example, the optimal λ is 10 −6 . Also SlimLogR requires small β and γ (i.e., the parameters for LogR component regularization), for example, the optimal β is 10 −6 and the optimal γ is 10 −2 . This indicates the very minor effects of these parameters on SlimLogR. We fix the optimal values for these parameters in Table 6 , 7 and 8, and study the effects only from ω and α. Table 6 , 7 and 8 demonstrate a very similar trend, that is, as ω becomes smaller (i.e., the weight on LogR component becomes lower in SlimLogR), all rec t , prec t and acc t first increase and then decrease, and the optimal ω is around 5. This represents a trade-off between the SLIM component and the LogR component in SlimLogR. Empirically more weight should be put on the LogR component than on SLIM component. This may indicate that ADR label prediction is more difficult than co-prescription pattern learning. Similarly, as α becomes smaller (i.e., the regularization on parameter W of SLIM becomes less), all rec t , prec t and acc t also first increase and then decrease, and the optimal α is around [10, 50] . Smaller α will introduce larger values in W compared to larger α, and thus the relatively small optimal α indicates that W captures strong patterns from prescriptions. Table 9 presents the performance of the optimal SlimLogR in with LogR s when N = 5, 10, 20 to-avoid drugs are recommended. As SlimLogR in recommends more to-avoid drugs, the performance in terms of all rec t , prec t and acc t increases. This indicates the capability of SlimLogR in in correctly ranking true to-avoid drugs in the top of its recommendations.
Parameter Study

Top-N Performance
Co-Prescription Patterns
We consider W + and W − from SlimLogR in of the best performance (i.e., ω = 5, α = 20). W + /W − captures the co-prescription patterns among drugs that often appear in ADR inducing/no-ADR inducing prescriptions, respectively. The learned W + has a density 3.6%, and its top-5 largest values correspond to the following drug pairs: (desogestrel, ethinyl estradiol), (phenylephrine, hydrochlorothiazide), (salmeterol, fluticasone propionate), (hydrocodone, acetaminophen), (ethinyl estradiol, etonogestrel). These drug pairs are frequently prescribed together in A + . The number of prescriptions in A + that contain these drug pairs is 38, 32, 44, 133 and 38, respectively, compared to the average number of A + prescriptions of all possible drug pairs, which is 1.22. Many of the co-prescribed drugs share similar medical purposes. For example, salmeterol and fluticasone propionate are prescribed together to control and prevent symptoms caused by asthma or ongoing lung disease. Ethinyl estradiol and etonogestrel are prescribed together for birth control, as well as ethinyl estradiol and desogestrel. Hydrocodone and acetaminophenare frequently are taken together to treat pains and reduce fever.
The learned W − has a density 0.8%, and its top-5 largest values correspond to the following drug pairs: (lopinavir, ritonavir), (norelgestromin, ethinyl estradiol), (tenofovir, emtricitabine), (emtricitabine, tenofovir), (salmeterol, fluticasone propionate) These drug pairs are also frequently co-prescribed in A − . The number of A − prescriptions with these drugs pairs is 36, 23, 35, 35 and 35, respectively, compared to 1.11, the average number of A − prescriptions of all possible drug pairs. These drugs pairs also share similar medical purposes. For example, lopinavir and ritonavir, and tenofovir and emtricitabine are commonly used in HIV cocktail therapy. Norelgestromin and ethinyl estradiol are co-prescribed for birth control.
In the corresponding learned x (i.e., the parameter in the LogR component), the top-2 largest values correspond to drug simvastatin and atorvastatin. These two drugs have been reported in SIDER Side Effect Resource 3 as to induce myopathy. 28.72% of the ADR inducing prescriptions have at least one of these two drugs. Table 10 presents some examples of prescriptions and their recommended to-avoid drugs from SlimLogR such that the corresponding new prescriptions are true positive. Drugs that are reported in SIDER to induce myopathy are bold. Based on whether the prescriptions have myopathy-inducing drugs or not, and whether the recommended drugs induce myopathy or not, all the new prescriptions can be classified into four categories (corresponding to the four row blocks in Table 10 ). Note that in the last category, even the prescriptions do not contain any myopathy-inducing drugs, SlimLogR is able to recommend other non-ADR inducing drugs such that the new prescriptions will induce myopathy. This demonstrates the strong capability of SlimLogR for co-prescription pattern learning and ADR label prediction.
Case Study
DISCUSSIONS AND CONCLUSIONS
In this paper, we formally formulated the to-avoid drug recommendation problem and the safe drug recommendation problem. We developed a joint sparse linear recommendation and logistic regression model (SlimLogR) to tackle the recommendation problems, and developed real datasets and new evaluation protocols to evaluate the model. Our experiments demonstrate strong performance of SlimLogR compared to other methods.
In SlimLogR, we use simplistic linear models. Non-linear models (for both recommendation and label prediction) together may be able to better discover co-prescription patterns and predict labels jointly. We will investigate non-linear models in the future work. Column of "N" represents the number of recommended drugs. Columns of "A FAERS " and "A * " represent that "A FAERS " and "A * " are used as A pool , respectively. The bold performance is the best under the corresponding metrics in each column. Also it is common that DDIs induce multiple ADRs simultaneously. This problem is substantially more difficult but deserve future investigation.
